ArticlePloS one2025
The reverse association between riboflavin intake and Helicobacter pylori infection in US adults: A cross-sectional study.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aimed to examine the association between dietary riboflavin (vitamin B2) intake and Helicobacter pylori infection prevalence among U.S. adults, addressing the growing interest in nutritional strategies for microbial pathogenesis modulation.
methodsWe analyzed data from 2,895 participants in the 1999-2000 National Health and Nutrition Examination Survey (NHANES) with complete dietary and H. pylori serology records. Multivariable logistic regression models adjusted for sociodemographic, clinical, and nutritional covariates were employed to assess riboflavin-infection relationships. Dose-response patterns were evaluated using restricted cubic splines, and subgroup analyses tested heterogeneity across population strata.
resultsThe overall H. pylori seropositivity rate was 44.2%. Higher riboflavin intake exhibited a dose-dependent inverse association with infection risk. Compared to the lowest quartile (Q1 ≤ 1.13 mg/day), adjusted odds ratios (95% CI) for Q2 (1.14-1.64 mg/day), Q3 (1.65-2.34 mg/day), and Q4 (≥2.35 mg/day) were 0.77 (0.60-0.99), 0.63 (0.48-0.84), and 0.62 (0.41-0.94), respectively. Spline analysis confirmed a near-linear risk reduction with increasing intake.
conclusionThese findings suggest that dietary riboflavin may inversely correlate with H. pylori infection in a dose-responsive manner, potentially mediated through mitochondrial function preservation, oxidative stress reduction, and gut microbiota modulation. While observational design precludes causal inference, the results underscore the need for prospective studies evaluating riboflavin's role in infection prevention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.